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Objective: To evaluate the safety, tolerability, and pharmacokinetics of soticlestat, a first-in-class cholesterol 24hydroxylase inhibitor, in adults with developmental and/or epileptic encephalopathies (DEE).
Methods: The study comprised a 30-day, randomized, double-blind, placebo-controlled phase (Part A), followed
by a 55-day open-label phase (Part B) (ClinicalTrials.gov ID: NCT03166215) . In Part A, patients with DEE and at
least one bilateral motor seizure during the 4-week prospective baseline period were randomized 4:1 to receive
soticlestat or placebo, in addition to their usual antiseizure medication. In Part B, all patients received open-label
soticlestat. Soticlestat doses were titrated according to tolerability to a maximum of 300 mg twice daily (BID).
Safety evaluations included the incidence of treatment-emergent adverse events (TEAEs). Plasma soticlestat
concentrations were measured at various times for determination of multiple-dose pharmacokinetics and 24Shydroxycholesterol (24HC). Efficacy was assessed by evaluation of changes in seizure frequency from baseline.
Results: Eighteen patients (median age, 28.5 years) were enrolled and randomized, and 14 (78 %) completed the
study. In Part A, TEAEs occurred in 71.4 % of soticlestat-treated patients and 100 % of placebo-treated patients.
In Part B, the overall incidence of TEAEs was 68.8 %. In Part A, TEAEs that occurred in more than one patient in
the soticlestat group were dysarthria (n = 3, 21.4 %), lethargy (n = 2, 14.3 %), upper respiratory tract infection
(n = 2, 14.3 %), fatigue (n = 2, 14.3 %), and headache (n = 2, 14.3 %). Four patients discontinued treatment
because of TEAEs, of whom two reported drug-related seizure clusters as serious TEAEs. There were no deaths.
Pharmacokinetic analysis showed dose-dependent increases in systemic exposure and peak plasma soticlestat
concentrations. At the end of Part B, the overall mean percent change from baseline in plasma 24HC was − 80.97
%. Changes from baseline in median seizure frequency were +16.71 % and +22.16 % in the soticlestat and
placebo groups, respectively, in Part A, and − 36.38 % in all participants in Part B.
Conclusion: Soticlestat was well tolerated at doses of up to 300 mg BID and was associated with a reduction in
median seizure frequency over the study duration. Further studies are warranted to assess the possible efficacy of
soticlestat as adjunctive therapy in patients with DEEs such as Dravet syndrome and Lennox–Gastaut syndrome.

Abbreviations: 24HC, 24S-hydroxycholesterol; ABC-C, Aberrant Behavior Checklist-Community Edition; ASM, antiseizure medication; AUC0–τ, area under the
plasma concentration–time curve during a dosing interval; BID, twice daily; CH24H, cholesterol 24-hydroxylase; C-SSRS, Columbia-Suicide Severity Rating Scale;
Ctrough, observed plasma concentration at the end of a dosing interval; DEE, developmental and/or epileptic encephalopathies; DS, Dravet syndrome; ECG, elec
trocardiogram; FAS, full analysis set; LGS, Lennox–Gastaut syndrome; PD, pharmacodynamics; PK, pharmacokinetics; SAE, serious adverse event; TEAE, treatmentemergent adverse event.
* Corresponding author at: 35 Landsdowne St., Cambridge, MA, 02139, USA.
E-mail address: Dimitrios.arkilo@takeda.com (D. Arkilo).
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1. Introduction

neural hyperexcitation, such as DEEs (Nishi et al., 2020).
This phase 1b/2a clinical study examined the safety, tolerability,
pharmacokinetics (PK), and pharmacodynamics (PD) of soticlestat as
adjunctive therapy in adults with a diagnosis of DEE who demonstrated
bilateral motor seizures.

1.1. Epileptic encephalopathies
The developmental and/or epileptic encephalopathies (DEE) group
of rare and severe epilepsies affects approximately 100,000–200,000
people in the USA, is characterized by multiple seizure types and
developmental delay or regression, and incorporates a number of
orphan syndromes, including Lennox–Gastaut syndrome (LGS; esti
mated prevalence 1–5 per 10,000 worldwide) and Dravet syndrome (DS;
estimated prevalence 1 per 15,700 individuals in the USA) (Scheffer
et al., 2017; Steward et al., 2019; Trevathan et al., 1997; Wu et al.,
2015). Making an early diagnosis is often critical as many patients with
DEE experience daily seizures, which cause significant morbidity and
quick deterioration of quality of life. These rare neurodevelopmental
conditions often cause seizures that are difficult to control and are
highly resistant to multiple conventional antiseizure medications
(ASMs) (Scheffer et al., 2017; Steward et al., 2019), thus representing a
significant unmet medical need. Currently, some DEE do not have access
to US Food and Drug Administration-approved therapies, whereas DS
and LGS have only limited options.
The investigational drug soticlestat (TAK-935/OV935) is a first-inclass, selective inhibitor of cholesterol 24-hydroxylase (CH24H) being
evaluated for adjunctive treatment of seizures in association with DEE.
This novel mechanism of action is thought to have the potential to
reduce seizure frequency and severity, with therapeutic benefit in epi
lepsy and disorders associated with overactivated glutamatergic regu
lation (Nishi et al., 2020), presumably through the inhibition of CH24H
and associated reduction of the cholesterol metabolite 24S-hydrox
ycholesterol (24HC).
Although the role of CH24H in the pathology of disorders of the
central nervous system has not been fully elucidated (Famer et al., 2007;
Fourgeux et al., 2009; Jeitner et al., 2011), it has been shown that
CH24H is predominantly expressed in neurons (Lund et al., 2003; Rus
sell et al., 2009; Xie et al., 2003), and preclinical and human postmortem
studies have shown that neurodegeneration and brain insults may lead
to induction of CH24H expression in reactive astrocytes and microglia
(Bogdanovic et al., 2001; Cartagena et al., 2008). This ‘ectopic’
expression in glia lowers cholesterol levels in the cellular environment
(Cartagena et al., 2008), leading to disruption of plasma-membrane lipid
rafts and astrocytic glutamate homeostasis, with markedly increased
levels of extracellular glutamate, which is normally sequestered by
glutamate transporters on neighboring astrocytes (Perez-Nievas and
Serrano-Pozo, 2018; Tian et al., 2010). This may contribute to enhanced
glutamatergic activity observed in epilepsy disorders (Chapman, 2000).
When CH24H converts cholesterol to 24HC, the circulating levels of
this metabolite will increase, which may further contribute to underly
ing pathophysiological processes. Excessive levels of extracellular
glutamate and 24HC are thought to play major roles in excitotoxicity,
either through sustained activation of the N-methyl-D-aspartate receptor
channel or as a positive allosteric modulator of the receptor (Paul et al.,
2013). In addition, neuronal 24HC may have a role in the regulation of
glial function, including potassium homeostasis and inflammation, as
well as neurotoxic processes such as oxidative stress and necroptosis
(Noguchi et al., 2014; Nury et al., 2015; Vo et al., 2015). Soticlestat is
thought to reduce excessive glutamatergic action by reducing levels of
24HC through its inhibition of CH24H.
Preclinical evidence from CH24H-knockout mice compared with
wild-type mice has shown that soticlestat selectively binds to CH24H
(Nishi et al., 2020). In a transgenic mouse model carrying mutated
human amyloid precursor protein and presenilin 1 (APP/PS1-Tg),
characterized by an excitatory/inhibitory imbalance, soticlestat
dose-dependently reduced 24HC. Furthermore, in APP/PS1-Tg mice,
soticlestat was shown to suppress potassium-evoked extracellular
glutamate elevations suggesting that soticlestat-mediated inhibition of
CH24H may have therapeutic potential for disorders associated with

2. Material and methods
2.1. Study design
The study (ClinicalTrials.gov ID: NCT03166215) consisted of two
periods: a randomized, double-blind, placebo-controlled Part A, in
which the participants were randomized to receive soticlestat or
matching placebo concomitantly with standard ASM treatment regi
mens; and an open-label Part B, which followed immediately upon the
conclusion of Part A (Fig. 1). In Part B, all participants received soti
clestat to investigate its safety, tolerability, PK, and PD in an open-label
manner.
The study was conducted in accordance with the ethical principles of
Good Clinical Practice, according to the International Conference on
Harmonisation guidelines (International Council for Harmonisation,
2016), and all applicable country-specific regulations. The study pro
tocol (available at https://clinicaltrials.gov/ct2/show/NCT03166215)
was approved by an independent ethics committee or institutional re
view board at each site according to local regulations. Written informed
consent was obtained from the participants, or their legally authorized
representative, at the time of the screening (Visit 1), prior to any study
procedures.
2.1.1. Inclusion/exclusion criteria
Adults (age, 18–65 years inclusive) with DEE and an average of at
least two bilateral motor seizures per month during the 3 months prior
to enrollment entered a 4-week prospective baseline period. Those with
an average of at least one bilateral motor seizure during the baseline
period (i.e. drop seizures, tonic-clonic, tonic, bilateral clonic, atonic,
myoclonic-atonic, myoclonic-tonic-clonic, or focal seizures with bilat
eral hyperkinetic motor features) were eligible for the study.
Individuals with DEE were enrolled using the following inclusion
criteria: established diagnosis of DEE, such as LGS, DS, or tuberous
sclerosis complex; history of special education classes; full scale intel
ligence quotient < 70; or generalized background slowing (posterior
dominant rhythm persistently < 8 Hz) on interictal electroencephalo
gram. Other inclusion criteria included a stable regimen of 1–4 ASMs for
≥ 4 weeks before screening (Visit 1). Exclusion criteria included:
degenerative eye disease; an abnormal and clinically significant elec
trocardiogram (ECG) at screening (Visit 1); and admission to a medical
facility for treatment of status epilepticus requiring mechanical respi
ration in the 3 months prior to screening (Visit 1).
Concomitant stiripentol use was exclusionary, however, rescue
benzodiazepine use more than 3 times a week counted as an allowed
ASM. Participants were advised not to consume alcohol or drugs such as
cannabis (medical marijuana was allowed) during the study. No medi
cations were allowed, including over-the-counter products, without first
consulting with the investigator.
2.1.2. Objectives and endpoints
The primary objective of this study was to characterize the multipledose safety and tolerability profile of soticlestat in adults with a diag
nosis of DEE. The secondary objective was to characterize the multipledose PK profile of soticlestat in adults with DEE receiving concomitant
ASMs.
The primary endpoint was the percentage of participants with at
least one treatment-emergent adverse event (TEAE), as reported by the
participant or participants’ caregivers or observed by the investigator.
Additional safety assessments included clinical laboratory evaluations,
vital signs, ECG parameters, Columbia-Suicide Severity Rating Scale (C2
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Fig. 1. Study flow charts showing (A) study schematics and (B) participants disposition.
a
Did not meet entrance criteria (n = 5) and withdrawal by patient (n = 3).
b
Weakness (n = 1); difficulty with walking/worsening lethargy (n = 1).
c
Seizure cluster (n = 2).
BID, twice daily; PK, pharmacokinetics; Tx, treatment.

SSRS), and the Aberrant Behavior Checklist-Community Edition (ABCC). PK endpoints included population mean estimates of drug clearance,
volume of distribution of the central compartment, absorption rate
constant, volume of distribution of the peripheral compartment, inter
compartmental clearance, maximum observed plasma concentration,
area under the plasma concentration–time curve during a dosing inter
val (AUC0–τ), average plasma concentration at steady state, and
observed plasma concentration at the end of a dosing interval (Ctrough)
for soticlestat. Efficacy of soticlestat on seizure reduction was evaluated
as an exploratory endpoint.

2.2. Study parts, doses, and titrations
2.2.1. Screening/baseline
Demographic information included age, sex, Hispanic ethnicity, and
race. At screening (Visit 1), all caregivers were provided with a paper
seizure diary (booklet) and instructed to keep a daily written record of
all seizure events throughout the study up until the follow-up visit.
Participants and/or participants’ caregivers were required to capture
seizure type and frequency, monitor for any worsening of seizure fre
quency, and denote any seizure free days on a daily basis.
The 4-week prospective baseline period began after informed
3
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2.3.2. Safety/tolerability assessments
TEAEs, clinical laboratory tests, vital sign measurements (tempera
ture, blood pressure, heart rate, and respiratory rate), ECG parameters,
physical, neurological and ophthalmic examination findings, and CSSRS were used to assess safety and tolerability. Furthermore, the ABC-C
was used to measure the severity of a range of behaviors commonly
observed in individuals with intellectual and developmental disabilities.
TEAEs were summarized using descriptive statistics for Parts A and B
separately. No statistical testing was performed.

consent was signed. Seizure diary data was used for eligibility confir
mation and endpoint analysis. Participants had to exhibit at least one
bilateral motor seizure during the 4-week baseline period.
2.2.2. Part A
Part A was a randomized, placebo-controlled, double-blind period
consisting of a titration phase (Days 1–20) and a maintenance phase
(Days 21–30). On Day 1 (Visit 2), participants were randomized (4:1) to
soticlestat or matching placebo (orally or via gastrostomy tube/percu
taneous endoscopic gastrostomy tube) for 30 days.
Participants were initially administered soticlestat 100 mg twice
daily (BID; Days 1–10), then titrated up to 200 mg BID (Days 11–20),
and then 300 mg BID (Days 21–30). Those who could not tolerate the
100 mg BID dosage were withdrawn from the study. During Days 11–30,
the dosage could be reduced by 100 mg BID in participants who could
not tolerate the 200 mg BID or 300 mg BID dosages, or in those who
demonstrated safety concerns, based on the investigator’s judgment and
in consultation with the participant’s caregiver. Participants who had
received a reduced dose remained on that dose level until the end of Part
A. Three days after each titration step, participants were evaluated for
study-drug adherence, concomitant medication use, and TEAEs.

2.3.3. PK/PD assessments
Blood samples for the measurement of plasma concentrations of
soticlestat were collected before and after the morning dose on Days 1,
11, and 21 and before the morning dose on Days 31, 41, and 85, when
feasible. Plasma concentrations of soticlestat were measured by vali
dated high-performance liquid chromatography with tandem mass
spectrometry assays. PK parameters were determined from the concen
tration–time profiles for all evaluable participants using a population PK
approach.
Blood samples for PD measurement of baseline plasma 24HC levels
were collected at the screening visit, before and after the morning dose
on Days 1, 11, and 21, before the morning dose on Days 31, 41, and 85,
and on Day 121, when feasible. Plasma concentrations of 24HC were
measured by high-performance liquid chromatography with tandem
mass spectrometry.

2.2.3. Part B
Part B was an open-label extension period designed to explore
longer-term safety, tolerability, PK, and 24HC plasma levels of soticle
stat, and consisted of a titration, a maintenance, and a down-titration
phase. Efficacy of soticlestat on seizure frequency was investigated in
an exploratory manner. All participants who completed Part A were
given the option to continue to Part B and to return to the clinic on Day
31 (Visit 5).
In Part B, participants were initially administered 200 mg BID (Days
31–40), followed by 300 mg BID (Days 41–85, the maintenance phase).
The dosage could be reduced by 100 mg BID for those who could not
tolerate higher doses, or who demonstrated safety concerns, based on
the investigator’s judgment and in consultation with the participant’s
caregiver. Those who could not tolerate the 100 mg BID dosage were
withdrawn from the study. Participants who had received a reduced
dose remained on that dose level until the end of the maintenance phase
on Day 85 (Visit 7), at which time the dose level was tapered over 3–6
days. All participants were followed up for 30 days after the last dose for
safety.

2.3.4. Efficacy assessments
The effect of soticlestat on seizure frequency was evaluated using
percent changes from baseline in seizure frequency during Part A and
Part B. Participants with an average of at least one bilateral motor
seizure, excluding myoclonic jerks and spasms, during the 4-week
baseline period were included in the evaluation of this exploratory ef
ficacy endpoint.
The derivation of the monthly seizure frequency is described in the
Statistical Analysis Plan (available at https://clinicaltrials.gov/ct2/
show/NCT03166215). All bilateral motor seizures, except myoclonic
seizures, were included in the derivation. The baseline time period in
cludes all seizure diary data prior to study drug initiation on Day 1.
Because of the small number of participants, no missing data imputation
was performed.
The summaries of monthly seizure frequency and percent changes
from baseline for Parts A and B were provided. A post hoc sensitivity
analysis was performed for participants who were not taking per
ampanel. No inferential statistical analysis was performed.
Responders were evaluated in Part A and Part B post hoc. Two
responder categories were examined: participants who had 50 % to <
100 % reduction in primary seizure frequency and those who had 100 %
reduction (seizure free).

2.3. Statistical and analytical methods
Descriptive statistics were used to summarize data for continuous
and categorical variables. A formal sample size calculation was not
performed for this pilot study. All data analyses and figures were
generated using SAS System Version 9.4.
2.3.1. Analysis sets
The randomized set included all participants who had been
randomly assigned to treatment. The PK analysis set included those who
had received at least one dose of study drug and had at least one postdose measurable soticlestat plasma concentration. The PD analysis set
included those who had received at least one dose of study drug and had
at least one measurable plasma 24HC concentration.
The full analysis set (FAS) for Parts A and B included all participants
who had received at least one dose of study drug and had at least one
post-baseline value for assessment of the efficacy endpoints in Part A or
Part B. The FAS efficacy summaries were presented according to treat
ment assignment in Part A. The safety analysis set included those who
had received at least one dose of study drug, and the safety summaries
were presented according to the actual treatment they received. Seizure
frequency data from participants who completed Part B (completers)
were analyzed post hoc for Days 58–85 and 65–92, relative to the first
dose (soticlestat or placebo) date in Part A (Day 1).

3. Results
3.1. Demographics
Eighteen adults with DEE (median age [min, max], 28.5 [19, 45]
years) (Table 1), who had experienced at least one motor seizure during
the baseline period, were enrolled from 10 sites in North America. A
total of 14 participants (78 %) completed the study (Fig. 1A and B).
Seven participants were able to take the study medication without dose
adjustment and the other participants required various dose adjustments
(Table 2).
Participants had heterogeneous DEE diagnoses and presented with
multiple seizure types, including tonic, tonic-clonic, atonic, myoclonic,
clonic, and hyperkinetic seizures. Participants randomized to placebo
had fewer baseline seizures per 28 days than those randomized to soti
clestat (median, 10.10 and 33.75, respectively).
ASMs that were being taken by at least five participants at baseline
4
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Part A, a third participant reported an SAE of seizure cluster, which was
considered to be severe in intensity and not related to the study drug.
The same participant experienced two additional SAEs of seizure cluster
in Part B, which were both considered to be severe; one of the two latter
seizure clusters was considered to be related to the study drug, and the
patient withdrew from the study. The fourth participant reported an SAE
of seizure cluster, which was considered to be severe in intensity and
related to the study drug; therefore, the patient withdrew from the
study.
In addition to these four participants who discontinued, a fifth
participant experienced an SAE of seizure, which was considered to be of
moderate intensity and not related to the study drug. This patient did not
discontinue from the study. Therefore, in total, five seizure-related SAEs
were reported by three participants (Table 3).
Overall, no changes from baseline in clinical laboratory evaluations,
vital signs, ECG parameters, C-SSRS, and ABC-C were considered to be
clinically significant. One participant reported intellectual impairment
as an abnormal finding on the physical examination at Day 22 (Part A,
placebo group) and Day 87 (Part B, soticlestat), but not at screening.

Table 1
Participant demographics and diagnoses.
Placebo (n =
4)
Demographics
Age, years
Median (min, max)
Sex, n (%)
Male
Female
Race, n (%)
Caucasian
Black or African American
Not reported
Seizures at baseline, n per 28
days
Median (min, max)

Diagnoses, n (%)
Lennox–Gastaut syndrome
Epileptic encephalopathya
Partial seizures with
Frontal lobe epilepsy
Tuberous sclerosis complex
Cerebral dysgenesis
Hypothalamic hamartoma
Dravet syndrome
a

Soticlestat (n =
14)

Total (N =
18)

26.4 (19, 39)

28.7 (20, 45)

28.5 (19,
45)

4 (100)
–

10 (71)
4 (29)

14 (78)
4 (22)

3 (75)
1 (25)
–

13 (93)
–
1 (7)

16 (89)
1 (6)
1 (6)

10.10 (3.7,
49.5)

33.75 (3.4,
277.1)

–

1 (25)
1 (25)
–
–
–
–
–
–

4 (29)
3 (21.4)
1 (7)
1 (7)
1 (7)
1 (7)
1 (7)
1 (7)

5 (27.8)
4 (22.2)
1 (6)
1 (6)
1 (6)
1 (6)
1 (6)
1 (6)

3.2.2. PK/PD
Individual PK model parameter estimates at dosages of 100, 200, and
300 mg BID showed: mean clearance at 259.4, 195.8, and 190 L/h,
respectively; systemic exposures of soticlestat with mean steady state
area under the curve at 562.5, 1437, and 2188 ng/h/mL, respectively;
mean maximum observed concentration during a dosing interval at
steady state at 269.6, 639.8, and 975.3 ng/mL, respectively; and mean
Ctrough at 10.5, 26, and 30.2 ng/mL, respectively. These exposures were
similar to those seen in previous phase 1 studies in healthy volunteers.
In Part A, decreased plasma 24HC concentrations were found in the
soticlestat versus placebo group. Pre-dose mean percent changes from
baseline were − 69.76 % at Day 11 and − 76.88 % at Day 21 for soti
clestat versus − 4.30 % and − 0.71 % for placebo, respectively. At the end
of Part B (Day 85), the overall mean percent change from baseline in
plasma 24HC was − 80.97 %. Following soticlestat washout, plasma
24HC concentrations recovered to pretreatment levels (Fig. 2). The
24HC-lowering effect of soticlestat showed a trend towards plateauing
when soticlestat AUC0–τ was greater than 800 ng/h/mL.

Epileptic encephalopathies not otherwise specified.

Table 2
Dose adjustment pattern.
Dosage (mg BID)
Number of patients, n
(%) (N = 18)
4 (22.2)
1 (5.6)
1 (5.6)
1 (5.6)
1 (5.6)
1 (5.6)
1 (5.6)
1 (5.6)
7 (38.9)

Days
1–10
0
100
100
100
100
100
100
100
100

Days
11–20

Days
21–30

Days
31–40

Days
41–84

0

0

200

300

100
200
200
200
200
200
200

100

200

300

200
200
300
300
300

200
200
200
200
200

100
300
100
200
300

Table 3
Adverse events and serious adverse events.

Dosage (mg BID) in each interval reflects the final dose the patient is on during
that interval. 0 mg in Days 1–10, 11–20, and 21–30 intervals are patients who
were assigned to the placebo group in Part A of the study. BID, twice daily.

Part A
Placebo (n =
4)

Part B
Soticlestat (n =
14)

Frequency and severity
Number of participants with at least one TEAE, n (%)
AEs
4 (100)
10 (71.4)
Mild AE
4 (100)
7 (50)
Moderate
–
2 (14.3)
Severe
–
1 (7.1)
AE-related withdrawala
–
2 (14.3)
b,c
–
1 (7.1)
SAEs

were lamotrigine (n = 6 [33.3 %]), clobazam (n = 5 [27.8 %]), clo
nazepam (n = 5 [27.8 %]), and zonisamide (n = 5 [27.8 %]).
3.2. Study endpoints
3.2.1. Safety/tolerability
In the placebo-controlled Part A, the overall frequency of TEAEs was
lower in participants treated with soticlestat versus placebo (71.4 % and
100 %, respectively). In Part B, 68.8 % of participants experienced at
least one TEAE. In Part A, the only TEAEs that occurred in more than one
patient in the soticlestat group were dysarthria (three patients [21.4
%]), and lethargy, upper respiratory tract infection, fatigue, and head
ache (two patients each [14.3 %]). Of these, fatigue and headache were
reported in one placebo-treated patient each (25.0 %).
Four participants discontinued treatment while on soticlestat due to
TEAEs or serious adverse events (SAEs) – two each in Part A and Part B,
respectively. The first participant reported gait disturbance and leth
argy, which were both considered to be mild in intensity and related to
the study drug. The second participant reported asthenia, which was
considered to be moderate in intensity and related to the study drug. In

All (N =
16)

11 (68.8)
4 (25)
5 (31.3)
2 (12.5)
2 (12.5)
3 (18.8)

Number of participants with most common (≥ three participants overall [10 %])
non-serious AEs, n (%)d
Dysarthria
–
3 (21)
–
Fatigue
1 (25)
2 (14)
–
Headache
1 (25)
2 (14)
–
Insomnia
–
–
3 (19)
Lethargy
–
2 (14)
2 (12.5)
Seizure
–
–
3 (19)
Upper respiratory tract
–
2 (14)
1 (6)
infection

AE, adverse event; SAE, serious AE; TEAE, treatment-emergent AE.
a
Four participants discontinued in the soticlestat treatment arm.
b
SAEs were seizure clusters (n = 2) and seizure (n = 1).
c
There were no deaths across the soticlestat and placebo treatment arms.
d
All participants who received at least one dose of study drug.
5
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Fig. 2. Mean (SD) 24HC plasma levelsa.
a
Plasma 24HC levels assessed at baseline and pre-dose at Days 11–85 and Day 121 (~30 days following the end of the treatment). 24HC, 24S-hydroxycholesterol; SD,
standard deviation.

3.2.3. Seizure frequency
The baseline median seizure frequency per 28 days for participants
randomized to soticlestat (n = 14) and placebo (n = 4) were 33.75
(range, 3–277) and 10.10 (range, 4–50), respectively. In Part A (Days
2–31), the median percent change in seizure frequency from baseline
was +16.71 % (n = 14; range, − 63 % to +465 %) for soticlestat and
+22.16 % (n = 4; range, − 73 % to +142 %) for placebo. All three
participants treated with concomitant perampanel demonstrated seizure
increase compared with their baseline during Part A (percent change
from baseline seizure frequency, +107 %, +465 %, and +4 %). There
were no participants treated with perampanel in the placebo group. The
sensitivity analysis for participants who were not taking perampanel
showed that the baseline median seizure frequency was 30.9 per 28
days, with a median percent change from baseline of +7.54 % in Part A.
For all patients treated with soticlestat in Part B (maintenance phase;
Days 42–85), the median percent change in seizure frequency was
− 36.38 % (n = 16; range of % change, − 100 % to +398 %) from
baseline. For the three patients taking concomitant perampanel in Part
B, specifically during the maintenance phase, percent changes from
baseline seizure frequency were +297 %, +398 %, and +175 %. All
three participants completed the study. Excluding the participants tak
ing perampanel, the median percent change in seizure frequency was
− 44.66 % (n = 13) from baseline (Fig. 3). At Days 65–92, the last 28

days of treatment including tapering based on the scheduled visit, there
was a median percent change in seizures per 28 days of − 60.74 % in the
post hoc analysis of patients not taking perampanel who completed Part
B. The median seizure frequency for all completers, excluding those
taking perampanel, was 25.60 seizures per 28 days at baseline. Two
participants (12.5 %) had a 100 % reduction in seizure frequency
(seizure free) in last 4 weeks of treatment.
4. Discussion
The current study provides further evidence for the safety and
tolerability of soticlestat, which has previously been found to be
generally well tolerated at dosages of 1350 mg once daily in healthy
adults (Bialer et al., 2018; Chen et al., 2018; Wang et al., 2018). In
addition, the findings reported here show that the PK profile of soti
clestat is generally comparable between healthy adults and adult pa
tients with DEE. Furthermore, consistent with the pharmacology as well
as with previous observations in healthy individuals, a clear effect of
soticlestat exposure in reducing plasma 24HC levels was observed.
Based on these data, plasma 24HC levels may serve as a biomarker for
pharmacodynamic activity and central target engagement.
Due to the small number of participants and imbalanced randomi
zation, the effect of soticlestat on seizures was evaluated only with

Fig. 3. Seizure frequency in Part B in (A) the FAS including patients on perampanel and (B) the FAS excluding three patients on perampanel. Median change from
baseline in seizures as per the SAP. Based on an interval averaged over 28 days, excluding myoclonic seizures. The first dose day is study Day 1. FAS, full analysis set;
SAP, Statistical Analysis Plan.
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descriptive statistics. In both the soticlestat and the placebo treatment
groups, an increase in seizure frequency from baseline during the
double-blind treatment phase (Days 2–30) was observed. During openlabel treatment with soticlestat (Days 31–85 in Part B), there was a
modest reduction in seizure frequency relative to baseline. In addition,
three participants who received concomitant treatment with per
ampanel experienced an increased seizure frequency versus baseline. In
two of these individuals, seizures were exacerbated, although clear
conclusions cannot be made because of the small sample size. All three
participants who were taking perampanel completed the study. Given
that there is no known reason for a pharmacokinetic interaction between
soticlestat and perampanel, the increased seizure frequency observed in
the patients taking concomitant perampanel might be due to a phar
macodynamic interaction, or because of the variability in seizures
associated with the DEE itself. Future studies with larger sample sizes
would be needed to investigate the possible effects of soticlestat
adjunctive to perampanel. In addition, further evaluation is needed
regarding how specific etiologies influence treatment response, which
was not possible in the current study.
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